Close Menu
Invest Insider News
    Facebook X (Twitter) Instagram
    Thursday, November 19
    Facebook X (Twitter) Instagram Pinterest Vimeo
    Invest Insider News
    • Home
    • Bitcoin
    • Commodities
    • Finance
    • Investing
    • Property
    • Stock Market
    • Utilities
    Invest Insider News
    Home»Stock Market»Cipla share price: HSBC expects 13% upside for the stock post Q1 results on firm US prospects.
    Stock Market

    Cipla share price: HSBC expects 13% upside for the stock post Q1 results on firm US prospects.

    July 29, 20243 Mins Read


    Stock Market today: Cipla share price that has gained more than 24% year to date is trading near 52 week highs it scaled on Friday. Cipla had reported strong Q1 performance with net profit rising 17% YoY largely helped by improved operating performance as reported Ebitda grew 14% though revenue grew t a slower pace of 7% year-on-year.

    While India Business contributing more than 40% to overall grew 5%, The strong US sales growth lifted the show.

    Get Quick Cash in Minutes!

    Best Personal Loan at Lowest Interest Rates

    Instant Apply

    Robust US performance- Cipla’s US sales at $250 million contributing 31.2% to the first quarter revenue) grew 12.6% y-o-y and10.6% sequentially. The same was helped by market share gains for key launches like hormone drug lanreotide, respiratory inhaler albuterol generics as well as well supported by higher generic Revlimid sales .

    Cipla further has indicates that it should sustain US sales of $235-240 mullion in remaining quarters of FY25, which remains a key positive

    Analysts at HSBC Securities and Capital Markets (India) Pvt Ltd believe lanreotide generic has plenty of room to grow as the brand still holds 78% share of the overall lanreotide market. Further there are three more peptides launches planned by Cipla over the next 12 months starting in 2HFY25. HSBC analysts say that the traction in existing products and peptide launches should help Cipla to sustain US sales growth in FY25 and beyond. This should also ease concerns regarding delays in the launch of respiratory products, as generics of Abraxane and generic Advair which remain delayed due to pending plant clearances by USFDA.

    For the domestic business growth , Cipla has highlighted that India Branded Prescription Business grew at a healthy rate of 10% yoy. it was the softness in Trade Generics Business owing to distribution model change that led to softer overall growth for Cipla Business.



    HSBC continues to like Cipla’s healthy outlook in key segments (India, South Africa, the US), delivery on cost efficiencies, and prudent capital allocation. Notable HSBC says that the pipeline products – inhalers and peptides should provide comfort for the growth outlook of US sales despite a high base. Their target price for Cipla revised upwards to ₹1,775 (from ₹1,680) indicates more than 13% uspide for Cipla share price.



    Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before taking any investment decisions




    Topics You May Be Interested In



    Source link

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
    Previous ArticleJohnvents Industries DMCC Expands Global Reach with Launch of Uganda Operations, Targets Strategic Markets for Growth
    Next Article Bitcoin at Point of Cycle Right Before Parabolic Expansion, According to Crypto Analyst

    Related Posts

    Stock Market

    Crypto asset manager’s stock jumps 13% after full Ethereum sale

    November 18, 2026
    Stock Market

    REG – NCC Group PLC

    November 18, 2026
    Stock Market

    Stock market today: Dow and S&P 500 slide, Nasdaq rises in anticipation of Anthropic IPO

    November 18, 2026
    Leave A Reply Cancel Reply

    Top Posts

    How is the UK Commercial Property Market Performing?

    December 31, 2000

    How much are they in different states across the US?

    December 31, 2000

    A Guide To Becoming A Property Developer

    December 31, 2000
    Stay In Touch
    • Facebook
    • YouTube
    • TikTok
    • WhatsApp
    • Twitter
    • Instagram
    Latest Reviews
    Bitcoin

    Jack Dorsey’s Block pushes Bitcoin reserves above 9,000 BTC, stock surges 10%

    May 8, 2026
    Property

    Labubu tops China’s most globally influential online pop-culture IP list

    November 9, 2025
    Investing

    SWFL homeowners investing in water filtration systems

    October 22, 2024
    What's Hot

    L’analyste technique Katie Stockton révèle à quoi s’attendre pour Bitcoin et Ethereum – voici des résistances et des supports critiques

    April 23, 2025

    Why US Stocks Have More Risk Than Reward After Crash: Keller

    April 17, 2025

    Bitcoin Correction Is Over, Next Major Rally Beginning Now (Technical Analysis)

    August 9, 2024
    Most Popular

    UK Homeowners Could Stop Paying Council Tax and Stamp Duty Under Burnham Plans

    July 27, 2026

    Stock Market Today: Futures Little Changed to Conclude Mixed Week for Indexes; July Retail Sales Unexpectedly Decline

    August 14, 2026

    Indonesia posts first annual deflation in 25 years at 0.09% in February

    March 3, 2025
    Editor's Picks

    UK housing market debt falls as older generations pay off mortgages

    February 15, 2025

    Stock Market Today: Dow Opens Lower, Oil Prices Hit 5-Month High — Live Updates – WSJ

    October 23, 2026

    La hausse du Bitcoin serait-elle bloquée par les ventes massives des gros détenteurs de BTC ?

    July 4, 2025
    Facebook X (Twitter) Instagram Pinterest Vimeo
    • Get In Touch
    • Privacy Policy
    • Terms and Conditions
    © 2026 Invest Insider News

    Type above and press Enter to search. Press Esc to cancel.